Tuesday, 29 July 2014

Phamaceutical Sector: Merck & Company

Summer Investment Case: a post in the promising pharmaceutical sector. About North American Company Merck & Company which is posting an upbeat earnings per share result. It may well turn out to be a good buy opportunity. The following is from the Investing website Investing.com:

'' U.S. pharmaceutical giant Merck & Company (NYSE:MRK) reported better-than-expected second quarter earnings and revenue figures ahead of Tuesday’s opening bell, sending its shares modestly higher in pre-market trade.
Merck Q2 adjusted EPS $0.85, vs. $0.81 estimateMerck reports better than expected Q2 earnings, revenue
Merck said adjusted earnings came in at $0.85 per share in the second quarter, beating expectations for earnings of $0.81 per share.
The company’s second quarter revenue totaled $10.93 billion, above estimates for revenue of $10.61 billion.
The pharmaceutical company reaffirmed its 2014 revenue forecast and said it expected full-year earnings per share in a range between $3.43 to $3.53.
“We delivered a strong first half of the year, making progress in transforming our operating model, fueling innovation and managing costs, while focusing on our best opportunities”, said Kenneth C. Frazier, chairman and chief executive officer, Merck.
Following the release of the report, Merck (NYSE:MRK) saw shares rise 0.1% in pre-market trade.
Meanwhile, the outlook for U.S. equity markets was higher. The Dow indicated a gain of 0.2% at the open, the S&P 500 pointed to an increase of 0.15%, while Nasdaq 100 added 0.2%.''.

Good Investments to all readers of my Case. And if you happen to be on Holiday Break, a great time of enjoyment and refilling energies is what I recommend. To be ready for another certainly busy fall of the year.

Tuesday, 22 July 2014

If there is a major Breakout

I am posting today in the my suitcase Saxo Bank's John Hardy view about the possible path for the EURUSD exchange rate (currency pair). Hardy's analysis is seamlessly lucid, devoid of nuisance and bias. At the same time he recognises that failure to predict the right direction of the Financial Markets isn't necessarily a disadvantage if proper behaviour is triggered.

'' EURUSD is breaking lower - here are the next targets. EURUSD is breaking what is arguably a head and shoulders area - poking at the last shreds of flat-line support at the 2014 lows just below 1.3480. A break lower begs the question - where next? If we are to take the classic head and shoulders target, the target is close to 1.3000, but if we take a more typical 100% extension from the top of the right shoulder (an extension of the wave from the top of the head to the recent lows), we get a target of around 1.3210.

Other Fibonacci retracement levels are also bunched in this area as well, with the 61.8% retracement of the move from the critical old 1.2750 area coming in around 1.3225 and the 38.2% retracement of EU-crisis lows in July 2012 coming in closer to 1.3250. So we'll call 1.3250/1.3200 the next major target zone lower if this break through 1.3480/1.3500 holds.''